Federal Circ: AstraZeneca AB v Mylan Pharms on Claim Language v Ordinary Meaning

Vacating a stipulated infringement judgment based on an incorrect claim construction, Federal Circuit explained that it is improper to isolate claim language from the intrinsic evidence when determining the plain and ordinary meaning of a disputed term. AstraZeneca AB v. Mylan Pharms. Inc

Related Keywords

Richardg Taranto ,Mylan Pharms ,Astrazeneca ,Mylan Pharmaceuticals ,Drug Administration ,Us Court ,Federal Circuit ,Judge Taranto ,Legal ,Litigation ,Intellectual Property ,Strazeneca Abv Mylan Pharms ,Claim Language ,Intrinsic Evidence ,Lain And Ordinary Meaning ,